Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Department of Biology, University of Hawaii at Manoa, Honolulu, HI, USA.
Methods Mol Biol. 2023;2664:201-213. doi: 10.1007/978-1-0716-3179-9_15.
Cationic ferritin (CF) has been developed as a multimodal, targeted imaging tracer to directly detect and map nephrons in the kidney in vivo. Direct detection of functional nephrons provides a unique, sensitive biomarker to predict or monitor kidney disease progression. CF has been developed to map functional nephron number from magnetic resonance imaging (MRI) or positron emission tomography (PET). Previous preclinical imaging studies have used non-human-derived ferritin and commercial formulations that must still be developed for translation to clinical use. Here we describe the reproducible formulation of CF (either derived from horse or from human recombinant ferritin) optimized for intravenous injection and radiolabeling by PET. The human recombinant heteropolymer ferritin is spontaneously assembled in liquid culture (Escherichia coli, E. coli) and modified to form human recombinant cationic ferritin (HrCF) to mitigate potential immunologic reactions for use in humans.
阳离子铁蛋白 (CF) 已被开发为一种多模态、靶向成像示踪剂，可直接在体内检测和绘制肾脏中的肾单位。直接检测功能肾单位提供了一种独特、敏感的生物标志物，可用于预测或监测肾脏疾病的进展。CF 已被开发用于从磁共振成像 (MRI) 或正电子发射断层扫描 (PET) 中绘制功能肾单位数量。以前的临床前成像研究使用的是非人类来源的铁蛋白和商业制剂，这些制剂仍必须开发用于临床应用。在这里，我们描述了 CF（源自马或人重组铁蛋白）的可重复制剂，该制剂经过优化，可通过静脉注射和正电子发射断层扫描 (PET) 进行放射性标记。人重组杂聚物铁蛋白在液体培养物（大肠杆菌，E. coli）中自发组装，并经过修饰以形成人重组阳离子铁蛋白 (HrCF)，以减轻在人类中使用时可能产生的免疫反应。
